The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

Epinephrin (C01CA24, R03AA01)

Fusidinsäure (D06AX01)

Lipegfilgrastim (L03AA14)

Macrogol combinations (A06AD65)

Octreotid (H01CB02)

Pyridostigmine (N07AA02)

Tiotropium & Olodaterol (R03AL06)

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is 01.03.2023. Based on this, the contract term is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is 01.03.2023. Based on this, the contract term is a maximum of 24 months.